Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR Inhibition
Our results position CDK9 as a promising therapeutic target in TNBC, either alone or in combination with EGFR inhibition, provided that side effects associated with this combination treatment can be controlled.
Authors
- Solomon Tadesse (ORCID: https://orcid.org/0000-0002-9966-2236)
- Natalie Proost (ORCID: https://orcid.org/0009-0001-3282-793X)
- J. M. Martens
- Bastiaan van Gerwen
- Ronan P. McLaughlin
- Vera E. van der Noord (ORCID: https://orcid.org/0000-0002-9894-3239)
- Bob van de Water (ORCID: https://orcid.org/0000-0002-5839-2380)
- Jessica S. Karuntu (ORCID: https://orcid.org/0000-0003-4522-4721)
- Yinghui Zhang (ORCID: https://orcid.org/0000-0002-9108-0813)
- A. Mieke Timmermans
- Sarah Al Haj Diab
- Sunita K. C. Basnet
- Yi Long
- Jichao He
- Shudong Wang
- Sylvia E. Le Dévédec
- Chantal Pont
- Marieke van de Ven
- Bjørn Siteur
Institutions
- University of South Australia (AU)
- Cancer Genomics Centre (NL)
- Centre for Human Drug Research (NL)
- Erasmus MC Cancer Institute (NL)
Publication Details
- Journal
- Cellular Oncology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1007/s13402-025-01154-6
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Erasmus Medisch Centrum